Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:934579.
doi: 10.1155/2009/934579. Epub 2008 Oct 28.

Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor

Orapun Metadilogkul  1 , Vichai Jirathitikal, Aldar S Bourinbaiar
Affiliations

Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor

Orapun Metadilogkul et al. J Biomed Biotechnol. 2009.

Abstract

It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention-serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2-58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low viral load (R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P < .000001). The possible causes responsible for this unusual phenomenon are discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The appearance of V-1 Immunitor (V1) therapeutic oral AIDS vaccine.
See this image and copyright information in PMC

References

    1. Bartlett JG. Medical Management of HIV. Baltimore, Md, USA: Johns Hopkins University; 2003. (Chapter II, HIV Serology).
    1. MacDonald KL, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Annals of Internal Medicine. 1989;110(8):617–621. - PubMed
    1. Nakamura RM. Current status of clinical laboratory tests for the human immunodeficiency virus. Journal of Clinical Laboratory Analysis. 1990;4(4):295–306. - PubMed
    1. Gschnait F. HIV (HTLV III/LAV) serology: experiences based on more than 42,000 tests. Wiener Klinische Wochenschrift. 1987;99(15):536–539. (Ger). - PubMed
    1. Montagnier L, et al. Human immunodeficiency virus infection and AIDS in a person with negative serology. The Journal of Infectious Diseases. 1997;175(4):955–959. - PubMed

MeSH terms